Skip to main content
. 2014 Feb 4;136(9):3560–3571. doi: 10.1021/ja412001e

Figure 4.

Figure 4

Small animal PET images and PET quantification of intravenous injected tripods with different surface functionalization in mice bearing the U87MG human glioblastroma tumor. (a–c) Targeting of integrin αvβ3-postitive U87MG tumor in mice by RGD-functionalized tripods. Decay-corrected whole-body coronal PET images of nude mice bearing human U87MG tumors at 1, 4, 24, and 48 h after injection of 3.7 MBq of 64Cu-RGD-Au-tripod, 64Cu-RGD-Au-tripod with a blocking dose of c(RGDfC) (21 μmol of c(RGDfC)/kg of mouse body weight), and 64Cu–Au-tripod (200 pmol/kg of mouse body weight, or 2 mg/kg of mouse body weight). (d,f) PET quantification of tumors and major organs after intravenous injection to mice bearing subcutaneous U87MG glioma xenografts (n = 4 per group, data represent means ± SD). (g–i), Comparison of tumor and major organ uptake of 64Cu-RGD-Au-tripod, 64Cu-RGD-Au-tripod with a blocking dose of c(RGDfC), and 64Cu–Au-tripod for a time period up to 48 h after intravenous injection to U87MG tumor-bearing mice (n = 4 per group). Data represent mean ± SD ** P < 0.01, *P < 0.05 (two-sided Student’s t-test).